Skip to main content

Table 4 Patient demographics and clinical characteristics: treatment group differences

From: Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan

  NHA (± ADT)
(n = 367)
Chemo (± ADT)
(n = 231)
ADT alone
(n = 564)
p-value Test type Pairwise p-values
Age, mean, years (SD) 71.4 (7.1) 67.4 (7.2) 74.7 (7.7) < 0.0001 AN NHA vs Chemo: p < 0.001
NHA vs ADT alone: p < 0.001
Chemo vs ADT alone: p < 0.001
Employment status at time of data collection, n (%) 363 226 551 < 0.0001 CH NHA vs Chemo: p = 0.182
NHA vs ADT alone: p = 0.008
Chemo vs ADT alone: p < 0.001
 Working full-time 28 (7.7) 18 (8.0) 34 (6.2)    
 Working part-time 25 (6.9) 17 (7.5) 24 (4.4)    
 On long term sick leave 18 (5.0) 23 (10.2) 8 (1.5)    
 Homemaker 2 (0.6) 0 (0.0) 8 (1.5)    
 Student 1 (0.3) 0 (0.0) 0 (0.0)    
 Retired 279 (76.9) 159 (70.4) 459 (83.3)    
 Unemployed 10 (2.8) 9 (4.0) 18 (3.3)    
ECOG performance status at time of data collection, n (%) 367 230 559 0.0047 CH NHA vs Chemo: p = 0.309
NHA vs ADT alone: p < 0.001
Chemo vs ADT alone: p = 0.208
 0 80 (21.8) 65 (28.3) 185 (33.1)    
 1 217 (59.1) 121 (52.6) 252 (45.1)    
 2 58 (15.8) 38 (16.5) 96 (17.2)    
 3 10 (2.7) 6 (2.6) 21 (3.8)    
 4 2 (0.5) 0 (0.0) 5 (0.9)    
Disease status at time of data collection, n (%) 367 231 558 0.0129 CH NHA vs Chemo: p = 0.170
NHA vs ADT alone: p = 0.060
Chemo vs ADT alone: p = 0.010
 Disease progressing 21 (5.7) 10 (4.3) 17 (3.0)    
 Stable 131 (35.7) 68 (29.4) 228 (40.9)    
 Responding to treatment 215 (58.6) 153 (66.2) 313 (56.1)    
Patient’s family history of prostate cancer, n (%) 351 215 510 0.3223 CH NHA vs Chemo: p = 0.376
NHA vs ADT alone: p = 0.140
Chemo vs ADT alone: p = 0.770
 Has a family history 41 (11.7) 20 (9.3) 44 (8.6)    
 Does not have a family history 310 (88.3) 195 (90.7) 466 (91.4)    
Most recent PSA result at time of data collection (ng/mL), n 325 201 485 0.0061 AN NHA vs Chemo: p = 0.773
NHA vs ADT alone: p = 0.005
Chemo vs ADT alone: p = 0.002
 Mean (SD) 25.4 (77.9) 27.4 (74.0) 13.9 (37.4)    
Most recent haemoglobin test result at time of data collection(g/dL), n 186 139 285 0.0148 AN NHA vs Chemo: p = 0.006
NHA vs ADT alone: p = 0.045
Chemo vs ADT alone: p = 0.205
 Mean (SD) 12.3 (1.5) 11.8 (1.4) 12 (1.4)    
Most recent alkaline phosphatase result at time of data collection (U/L), n 153 131 251 0.1779 AN NHA vs Chemo: p = 0.160
NHA vs ADT alone: p = 0.868
Chemo vs ADT alone: p = 0.065
 Mean (SD) 202.4 (152.3) 177.5 (144) 204.8 (133.3)    
Risk status, n (%) 343 214 520 < 0.0001 CH NHA vs Chemo: p < 0.001
NHA vs ADT alone: p < 0.001
Chemo vs ADT alone: p < 0.001
 Low-risk 198 (57.7) 79 (36.9) 376 (72.3)    
 High-risk 145 (42.3) 135 (63.1) 144 (27.7)    
Disease volume, n (%) 320 203 457 < 0.0001 CH NHA vs Chemo: p < 0.001
NHA vs ADT alone: p < 0.001
Chemo vs ADT alone: p < 0.001
 Low volume 182 (56.9) 70 (34.5) 328 (71.8)    
 High volume 138 (43.1) 133 (65.5) 129 (28.2)    
Presence of bone metastases, n (%) 367 231 564 0.1442 CH NHA vs Chemo: p = 0.049
NHA vs ADT alone: p < 0.349
Chemo vs ADT alone: p < 0.183
 Patient has bone metastases 306 (83.4) 206 (89.2) 483 (85.6)    
 Patient does not have bone metastases 61 (16.6) 25 (10.8) 81 (14.4)    
Presence of brain metastases, n (%)     0.2747 CH NHA vs Chemo: p = 0.134
NHA vs ADT alone: p = 0.554
Chemo vs ADT alone: p = 0.257
 Patient has brain metastases 1 (0.3) 3 (1.3) 3 (0.5)    
 Patient does not have brain metastases 366 (99.7) 228 (98.7) 561 (99.5)    
Presence of lung metastases, n (%)     < 0.0001 CH NHA vs Chemo: p = 0.001
NHA vs ADT alone: p = 0.002
Chemo vs ADT alone: p < 0.001
 Patient has lung metastases 32 (8.7) 41 (17.7) 22 (3.9)    
 Patient does not have lung metastases 335 (91.3) 190 (82.3) 542 (96.1)    
Presence of pancreatic metastases, n (%)     0.1105 CH NHA vs Chemo: p = 0.074
NHA vs ADT alone: p = 0.420
Chemo vs ADT alone: p = 0.151
 Patient has pancreatic metastases 0 (0.0) 2 (0.9) 1 (0.2)    
 Patient does not have pancreatic metastases 367 (100.0) 229 (99.1) 563 (99.8)    
Presence of liver metastases, n (%)     < 0.0001 CH NHA vs Chemo: p = 0.002
NHA vs ADT alone: p < 0.001
Chemo vs ADT alone: p < 0.001
 Patient has liver metastases 26 (7.1) 35 (15.2) 11 (2.0)    
 Patient does not have liver metastases 341 (92.9) 196 (84.8) 553 (98.0)    
Presence of adrenal gland metastases, n (%)     0.0026 CH NHA vs Chemo: p = 0.670
NHA vs ADT alone: p < 0.001
Chemo vs ADT alone: p = 0.003
 Patient has adrenal gland metastases 10 (2.7) 5 (2.2) 1 (0.2)    
 Patient does not have adrenal gland metastases 357 (97.3) 226 (97.8) 563 (99.8)    
Presence of peritoneal metastases, n (%)     0.0001 CH NHA vs Chemo: p = 0.667
NHA vs ADT alone: p < 0.001
Chemo vs ADT alone: p < 0.001
 Patient has peritoneal metastases 17 (4.6) 9 (3.9) 3 (0.5)    
 Patient does not have peritoneal metastases 350 (95.4) 222 (96.1) 561 (99.5)    
Presence of non-regional/distant lymph node metastases, n (%)     0.0019 CH NHA vs Chemo: p = 0.683
NHA vs ADT alone: p = 0.004
Chemo vs ADT alone: p = 0.003
 Patient has non-regional/distant lymph node metastases 129 (35.1) 85 (36.8) 148 (26.2)    
 Patient does not have non-regional/distant lymph node metastases 238 (64.9) 146 (63.2) 416 (73.8)    
Presence of other metastases, n (%)     0.6136 CH NHA vs Chemo: p = 0.317
NHA vs ADT alone: p = 0.554
Chemo vs ADT alone: p = 0.589
Patient has other metastases 366 (99.7) 229 (99.1) 561 (99.5)    
Patient does not have other metastases 1 (0.3) 2 (0.9) 3 (0.5)    
  1. ADT androgen deprivation therapy, AN ANOVA, CH Chi-squared, Chemo chemotherapy, ECOG Eastern Cooperative Oncology Group, NHA novel hormonal agents, PSA prostate-specific antigen, SD standard deviation